RT Journal Article
SR Electronic
T1 Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5215
OP 5223
VO 37
IS 9
A1 LUSHUN CHALISE
A1 KAZUYA MOTOMURA
A1 FUMIHARU OHKA
A1 MASAKI HIRANO
A1 MASAHITO HARA
A1 YUSUKE NISHIMURA
A1 ATSUSHI NATSUME
A1 TOSHIHIKO WAKABAYASHI
YR 2017
UL http://ar.iiarjournals.org/content/37/9/5215.abstract
AB Background/Aim: In the current study, we aimed to compare DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy with high-dose methotrexate (HD-MTX) monotherapy plus whole-brain radiation therapy (WBRT) for newly-diagnosed primary central nervous system lymphoma (PCNSL), in terms of their efficacies and tolerability. Patients and Methods: A total of 21 consecutive patients with PCNSL were treated with DeVIC therapy and WBRT, between 2002 and 2010. From 2010 to 2014, 14 consecutive patients with PCNSL were treated with HD-MTX followed by WBRT. Results: Overall response rates of complete and partial response for initial chemotherapy were significantly better with DeVIC therapy (95.2%) than with HD-MTX monotherapy (50%). Furthermore, one-year and two-year progression-free survival (PFS) rates were better in the DeVIC cohort than in the HD-MTX cohort. DeVIC therapy yielded higher early response rates, longer PFS, and manageable adverse events, and may be potentially better for the treatment of cases that are refractory to MTX-based therapy. Conclusion: Our retrospective clinical study revealed that DeVIC therapy is comparable with that of HD-MTX monotherapy plus WBRT, for newly diagnosed PCNSL.